Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%. ([email protected])